HuGE Literature Finder
Records
1
-
5
PDCD1 gene polymorphisms as regulators of T-lymphocyte activity in cutaneous melanoma risk and prognosis. Pigment cell & melanoma research 2017 Nov . Gomez Gabriela V B, Rinck-Junior José A, Oliveira Cristiane, Silva Dennis H L, Mamoni Ronei L, Lourenço Gustavo J, Moraes Aparecida M, Lima Carmen S |
PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget 2017 5 8 (25): 41011-41020. Goltz Diane, Gevensleben Heidrun, Dietrich Joern, Schroeck Friederike, de Vos Luka, Droege Freya, Kristiansen Glen, Schroeck Andreas, Landsberg Jennifer, Bootz Friedrich, Dietrich Di |
Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. Journal of cancer research and clinical oncology 2016 Aug 142 (8): 1775-80. Yoon Shinkyo, Kang Byung Woog, Park Su Yeon, Kim Hye Jin, Park Jun Seok, Choi Gyu Seog, Kim Jong Gwa |
Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncoimmunology 2016 11 5 (10): e1221555. Goltz Diane, Gevensleben Heidrun, Dietrich Jörn, Ellinger Jörg, Landsberg Jennifer, Kristiansen Glen, Dietrich Di |
Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. The pharmacogenomics journal 2015 Mar . Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz H |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: